Even the Nasdaq Biotechnology Index, which tracks established biotech firms, is up 13% this year. The IPO crop is doing more than four times better than that.
The standout is VeraDermics Inc., a company developing a drug for pattern hair loss. Since going public in February, the company's shares have surged more than fivefold, making it the top-performing US IPO across all industries this year. Another example: Hemab Therapeutics Holdings Inc., which focuses on blood disorders, more than doubled after its May IPO.
But the real fuel came from three huge acquisitions announced in just the past month. AbbVie bought Apogee Therapeutics, GSK bought Nuvalent, and Vertex bought Crinetics Pharmaceuticals. Each deal was valued at $10 billion or more.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
Those big paydays did two things. They boosted the perceived value of other small biotech companies, and they put cash in the hands of investors who had been holding those stocks. That cash often flows right back into new IPOs.
Jack Bannister, a senior managing director at Leerink Partners, put it simply: "This is the healthiest biotech IPO market we have had in a long time."
A more predictable regulatory environment and important clinical trial results also helped. Seth Rubin, global head of equity capital markets at Stifel Financial, said large fund families are pushing more money into healthcare because the returns in smaller biotech stocks have proven there is real upside.
The largest deal of the year came from Parabilis Medicines Inc., a rare cancer specialist, which pulled in $770.6 million in June.
Those deals could price in late July or early August before the usual summer slowdown.
The big question is whether this run can last. Interest rates are still high, and rate hikes can make it harder to value biotech companies, which often have no revenue and promise profits years down the road.
But for now, the market is shrugging that off. Bannister said the sector is trading independently of rate concerns and moving counter to the AI trade. His view: "You have to park your money somewhere and relative to other opportunities right now biotech feels like it's not just a safe place, but a place that has real upside."
Rubin added that he does not think the market has gotten ahead of itself. The returns have been strong but not crazy, and the deal volume is still far below the more than 200 biotech companies that went public during the pandemic boom years of 2020 and 2021. That period turned out to be unsustainable.
The bottom line: Biotech IPOs are having a moment that reminds people what a hot sector looks like when the fundamentals actually support it. For investors who own biotech stocks directly or through funds, the recent wave of acquisitions and strong debut performances suggest the momentum may have room to run. And for anyone watching from the sidelines, the sector is worth paying attention to - not because it will keep up 55% returns forever, but because the forces driving it are real and not just hype.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
